コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and account for the development of herpetic neuralgia.
2 multiple sclerosis patients with trigeminal neuralgia.
3 r, and had an uncomplicated recovery without neuralgia.
4 t at risk of prolonged pain and postherpetic neuralgia.
5 y little pain, and there was no postherpetic neuralgia.
6 nt of chickenpox, shingles, and postherpetic neuralgia.
7 l nerve for medically intractable trigeminal neuralgia.
8 king in patients with presumed genitofemoral neuralgia.
9 effective for the diagnosis of genitofemoral neuralgia.
10 of Carbamazepine in treatment of Trigeminal Neuralgia.
11 er, which may be complicated by postherpetic neuralgia.
12 ndrome, Achilles tendinitis and medial nerve neuralgia.
13 ccount for the development of acute herpetic neuralgia.
14 shown striking similarities with trigeminal neuralgia.
15 gical concept of SUNCT, SUNA, and trigeminal neuralgia.
16 ical basis between SUNCT/SUNA and trigeminal neuralgia.
17 tial of EMA401 in patients with postherpetic neuralgia.
18 uritis with classical symptoms of peripheral neuralgia.
19 , which is often complicated by postherpetic neuralgia.
20 events such as xerophthalmia and trigeminal neuralgia.
21 or definitive management of chronic inguinal neuralgia.
22 thophysiology of pre- and typical trigeminal neuralgia.
23 d HZ severity and occurrence of postherpetic neuralgia.
24 d can be further complicated by postherpetic neuralgia.
25 th reduced HZ severity and less postherpetic neuralgia.
26 ed pain relief in patients with postherpetic neuralgia.
27 y a critical role in the genesis of herpetic neuralgia.
28 dults against herpes zoster and postherpetic neuralgia.
29 ed noninvasively in patients with trigeminal neuralgia.
30 ive pain score in patients with postherpetic neuralgia.
31 erpes zoster and 70-88% against postherpetic neuralgia.
32 complaints following surgery for trigeminal neuralgia.
33 ions of the surgical treatment of trigeminal neuralgia.
34 lodynia in this animal model of postherpetic neuralgia.
35 end point was the incidence of postherpetic neuralgia.
36 the unique clinical features of postherpetic neuralgia.
37 lt from the surgical treatment of trigeminal neuralgia.
38 nto the potential mechanisms of postherpetic neuralgia.
40 NS infections, 12 (CI: 5, 13); post-herpetic neuralgia, 11 (CI: 6, 17); and major neurological injuri
41 bo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among plac
43 ster and 3300 fewer episodes of postherpetic neuralgia among 5.5 million eligible individuals in the
48 ultations for herpes zoster and postherpetic neuralgia, and aggregated these data to estimate vaccine
49 the neuro-ophthalmic features of trigeminal neuralgia, and detail the neuro-ophthalmic side effects
51 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ,
52 ith autonomic symptoms (SUNA) and trigeminal neuralgia are considered different disorders, thus group
54 at persistent RSD/CRPS-I is a post-traumatic neuralgia associated with distal degeneration of small-d
55 complications, namely incisional hernias and neuralgia at the trocar sites, which can potentially be
56 .001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the inc
58 s or open surgical procedures for trigeminal neuralgia can result in corneal anesthesia, neurotrophic
59 ly) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of
60 reating diabetic neuropathy and postherpetic neuralgia compared with placebo, gabapentin and pregabal
63 al trials for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, generalized a
65 were aged 18-90 years, had had postherpetic neuralgia for at least 6 months, and had an average base
67 iew of surgical interventions for trigeminal neuralgia found not a single trial of what is becoming t
72 treatment of herpes zoster and postherpetic neuralgia in immunocompetent older adults are reviewed,
77 d severity of herpes zoster and postherpetic neuralgia increase with age in association with a progre
78 ities available for patients with trigeminal neuralgia intolerable or resistant to medical therapy.
81 ontrol.SIGNIFICANCE STATEMENT Acute herpetic neuralgia is the most important symptom of herpes zoster
84 e is now persuasive evidence that trigeminal neuralgia is usually caused by demyelination of trigemin
85 ted in the painful condition of postherpetic neuralgia, is regulated by the cytoplasmic domains of gB
87 er, which may be complicated by postherpetic neuralgia, myelitis, meningoencephalitis, and VZV vascul
88 -89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, and Sept 30, 20
89 atients (aged 22-89 years) with postherpetic neuralgia of at least 6 months' duration from 29 centres
91 eripheral nervous system (e.g. post-herpetic neuralgia or diabetic neuropathy) or to the central nerv
92 al manifestations and etiology of trigeminal neuralgia, outline the neuro-ophthalmic features of trig
96 tions of current treatments for postherpetic neuralgia (PHN) have led to the investigation of localis
100 that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occu
101 ferences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters.
102 al reactivation are at risk for postherpetic neuralgia (PHN), a painful and long-lasting complication
103 burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for t
104 ted with herpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommending the HZ vacc
105 often debilitating pain called postherpetic neuralgia (PHN), which can last for months after the dis
106 loping the painful condition of postherpetic neuralgia (PHN), which has been difficult to treat becau
107 ir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting af
112 of zoster (group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group
113 t patients with vessel-associated trigeminal neuralgia, probably because the resulting separation of
114 s aged 18-80 years with confirmed trigeminal neuralgia received open-label, BIIB074 150 mg three time
115 ded peripheral visual field loss, trigeminal neuralgia, recurrent Bell's palsy, and pulsatile tinnitu
116 idence on whether SUNCT, SUNA and trigeminal neuralgia should be considered separate entities or vari
117 in turn mediates the development of herpetic neuralgia through downregulation of the inwardly rectify
118 eral surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most repor
119 However little is known about how trigeminal neuralgia (TN), a condition in which trigeminal stimulat
120 lia that account for the genesis of herpetic neuralgia using a murine model of Herpes Simplex Virus T
121 confirmed intractable unilateral trigeminal neuralgia were measured before treatment with gamma knif
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。